A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Tumors or cancer of the ADRENAL GLANDS.
An inorganic compound that is used as a source of iodine in thyrotoxic crisis and in the preparation of thyrotoxic patients for thyroidectomy. (From Dorland, 27th ed)
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
A specialty field of radiology concerned with diagnostic, therapeutic, and investigative use of radioactive compounds in a pharmaceutical form.
A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.
Discussions, descriptions or catalogs of public displays or items representative of a given subject.
Persons as individuals (e.g., ABORTION APPLICANTS) or as members of a group (e.g., HISPANIC AMERICANS). It is not used for members of the various professions (e.g., PHYSICIANS) or occupations (e.g., LIBRARIANS) for which OCCUPATIONAL GROUPS is available.
Conferences, conventions or formal meetings usually attended by delegates representing a special field of interest.
The interaction of persons or groups of persons representing various nations in the pursuit of a common goal or interest.
Authoritative treatises on drugs and preparations, their description, formulation, analytic composition, physical constants, main chemical properties used in identification, standards for strength, purity, and dosage, chemical tests for determining identity and purity, etc. They are usually published under governmental jurisdiction (e.g., USP, the United States Pharmacopoeia; BP, British Pharmacopoeia; P. Helv., the Swiss Pharmacopoeia). They differ from FORMULARIES in that they are far more complete: formularies tend to be mere listings of formulas and prescriptions.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.

Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. (1/545)

Impaired cardiac sympathetic activity can be evaluated by 123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) inhibitors. Patients were studied before treatment, after 5 mo of treatment (only in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer injection. New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M were more improved in group A than in group B (P < 0.05). LVEF was significantly increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac sympathetic activity evaluated by MIBG images improved after the beta-blocker therapy more than with the treatment that used ACE inhibitors.  (+info)

Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. (2/545)

Norepinephrine (NE) reuptake function is impaired in heart failure and this may participate in myocyte hyperstimulation by the neurotransmitter. This alteration can be assessed by 123I-metaiodobenzylguanidine (MIBG) scintigraphy. METHODS: To determine whether the impairment of neuronal NE reuptake was reversible after metoprolol therapy, we studied 18 patients (43+/-7 y) with idiopathic dilated cardiomyopathy who were stabilized at least for 3 mo with captopril and diuretics. Patients underwent, before and after 6 mo of therapy with metoprolol, measurements of radionuclide left ventricular ejection fraction (LVEF), maximal oxygen consumption and plasma NE concentration. The cardiac adrenergic innervation function was scintigraphically assessed with MIBG uptake and release measurements on the planar images obtained 20 min and 4 h after tracer injection. To evaluate whether metoprolol had a direct interaction with cardiac MIBG uptake and release, six normal subjects were studied before and after a 1-mo metoprolol intake. RESULTS: In controls, neither cardiac MIBG uptake and release nor circulating NE concentration changed after the 1-mo metoprolol intake. Conversely, after a 6-mo therapy with metoprolol, patients showed increased cardiac MIBG uptake (129%+/-10% versus 138%+/-17%; P = 0.009), unchanged cardiac MIBG release and decreased plasma NE concentration (0.930+/-412 versus 0.721+/-0.370 ng/mL; P = 0.02). In parallel, patients showed improved New York Heart Association class (2.44+/-0.51 versus 2.05+/-0.23; P = 0.004) and increased LVEF (20%+/-8% versus 27%+/-8%; P = 0.0005), whereas maximal oxygen uptake remained unchanged. CONCLUSION: Thus, a parallel improvement of myocardial NE reuptake and of hemodynamics was observed after a 6-mo metoprolol therapy, suggesting that such agents may be beneficial in heart failure by directly protecting the myocardium against excessive NE stimulation.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (3/545)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG). (4/545)

meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the carcinoid syndrome, in which MIBG proved to be effective in 60% of the patients. Oral MIBG administration might be convenient to maintain palliation and possibly improve the percentage of responders. We have, therefore, investigated the feasibility of oral administration of MIBG in an animal model. Orally administered MIBG demonstrated a bioavailability of 59%, with a maximal tolerated dose of 60 mg kg(-1). The first and only toxicity encountered was a decrease in renal function, measured by a reduced clearance of [51Cr]EDTA and accompanied by histological tubular damage. Repeated MIBG administration of 40 mg kg(-1) for 5 sequential days or of 20 mg kg(-1) for two courses of 5 sequential days with a 2-day interval did not affect renal clearance and was not accompanied by histological abnormalities in kidney, stomach, intestines, liver, heart, lungs, thymus, salivary glands and testes. Because of a sufficient bioavailability in absence of gastrointestinal toxicity, MIBG is considered suitable for further clinical investigation of repeated oral administration in patients.  (+info)

Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. (5/545)

OBJECTIVES: This prospective study was undertaken to correlate early and late metaiodobenzylguanidine (MIBG) cardiac uptake with cardiac hemodynamics and exercise capacity in patients with heart failure and to compare their prognostic values with that of peak oxygen uptake (VO2). BACKGROUND: The cardiac fixation of MIBG reflects presynaptic uptake and is reduced in heart failure. Whether it is related to exercise capacity and has better prognostic value than peak VO2 is unknown. METHODS: Ninety-three patients with heart failure (ejection fraction <45%) were studied with planar MIBG imaging, cardiopulmonary exercise tests and hemodynamics (n = 44). Early (20 min) and late (4 h) MIBG acquisition, as well as their ratio (washout, WO) were determined. Prognostic value was assessed by survival curves (Kaplan-Meier method) and uni- and multivariate Cox analyses. RESULTS: Late cardiac MIBG uptake was reduced (131+/-20%, normal values 192+/-42%) and correlated with ejection fraction (r = 0.49), cardiac index (r = 0.40) and pulmonary wedge pressure (r = -0.35). There was a significant correlation between peak VO2 and MIBG uptake (r = 0.41, p < 0.0001). With a mean follow-up of 10+/-8 months, both late MIBG uptake (p = 0.04) and peak VO2 (p < 0.0001) were predictive of death or heart transplantation, but only peak VO2 emerged by multivariate analysis. Neither early MIBG uptake nor WO yielded significant insights beyond those provided by late MIBG uptake. CONCLUSIONS: Metaiodobenzylguanidine uptake has prognostic value in patients with wide ranges of heart failure, but peak VO2 remains the most powerful prognostic index.  (+info)

Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. (6/545)

Myocardial imaging with 123I-metaiodobenzylguanidine (MIBG) was performed on 35 patients with Parkinson's disease and 24 control subjects to evaluate cardiac sympathetic function in patients with Parkinson's disease, verify this phenomenon and examine whether myocardial MIBG uptake and clearance are correlated with the clinical severity of Parkinson's disease. METHODS: We studied 35 patients with Parkinson's disease and 24 control subjects with other central nervous system diseases. The latter group consisted of 12 subjects with other neurodegenerative disorders (4 with spinocerebellar degeneration, 2 with amyotrophic lateral sclerosis, 3 with progressive supranuclear palsy and 3 with corticobasal degeneration and 12 patients with cerebral infarction (CI), 6 with vascular parkinsonism and 6 without it. Early and delayed images of the anterior view were obtained 15 min and 4 h after injection of 123I-MIBG, respectively. MIBG uptake was quantified by calculating a heart-to-mediastinum count (H/M) ratio. RESULTS: The H/M ratio was markedly reduced in the patients with Parkinson's disease (II to V on the Hoehn and Yahr scale) compared with the control subjects. None of the subjects with neurodegenerative diseases showed a marked decrease in myocardial MIBG uptake nor did any subject with CI. CONCLUSION: Our findings indicate that, in Parkinson's disease, a reduction in myocardial MIBG uptake is a very common, specific phenomenon that can be used to detect cardiac autonomic dysfunction to diagnose Parkinson's disease, particularly in patients without typical signs and symptoms.  (+info)

Myocardial stunning caused by sympathetic nerve injury after an operation on cervical vertebrae. (7/545)

In this case, electrocardiographic inverted T waves appeared after cervical laminaplasty and echocardiogram showed temporary wall motion abnormality. Myocardial metaiodobenzylguanidine (MIBG) uptake was obviously reduced in the same area where the wall motion abnormalities appeared in the echocardiogram, although no abnormalities were detected with myocardial thallium scintigraphy and coronary angiography. The myocardial stunning was caused by injury to the sympathetic nerves from a surgical procedure on the cervical vertebrae.  (+info)

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. (8/545)

OBJECTIVES: (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is clinically used to estimate local myocardial sympathetic nerve damage in some forms of heart disease, autonomic nerve disturbance in diabetic neuropathy, and disturbance of the autonomic nervous system in neurodegenerative disease. In the present study, examinations were performed to clarify (1) the proportion of cardiac sympathetic nerve disturbance in Parkinson's disease, (2) the usefulness of (123)I-MIBG myocardial scintigraphy to detect sympathetic nerve disturbances compared with autonomic function tests, (3) cardiac function in patients who have a decreased MIBG uptake in (123)I-MIBG myocardial scintigraphy, (4) the usefulness of (123)I-MIBG myocardial scintigraphy to differentiate Parkinson's disease from the other neurological diseases mimicking it. METHODS: (123)I-MIBG myocardial scintigraphy was performed, together with autonomic function tests and cardiac examinations in 46 patients with Parkinson's disease and 25 patients with vascular parkinsonism, essential tremor, or multiple system atrophy. RESULTS: In an anterior image study, the average count per pixel in heart to mediastinum (H/M) ratio decreased in 80% of the patients with Parkinson's disease in the early phase and 84% in the late phase. The mean H/M ratio in Parkinson's disease was significantly lower than that in controls and the other diseases. The H/M ratio tended to decrease with the disease progression. In almost half of the patients in Hoehn and Yahr stage I, the H/M ratio was already decreased. The sympathetic skin response in upper and lower limbs, head up tilt test, and coefficient of variation of R-R interval were abnormal in 17%, 31%, 30%, and 17% of the patients, respectively. All the patients with abnormal autonomic functions were in Hoehn and Yahr stage III, IV, or V. Echocardiography showed normal left ventricular function. Twenty four hour Holter electrocardiography detected no serious arrhythmias except for one patient with non-sustained ventricular tachycardia. CONCLUSION: (123)I-MIBG myocardial scintigraphy might detect early disturbances of the sympathetic nervous system in Parkinson's disease and might give useful diagnostic information to differentiate vascular parkinsonism, essential tremor, and multiple system atrophy from Parkinson's disease.  (+info)

In 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy, the early heart-to-mediastinum (H/M) ratio is considered to reflect the density of the cardiac sympathetic nerve endings, washout rate (WR) is an indicator of the cardiac sympathetic tone, and the delayed H/M ratio reflects both. The Delayed H/M ratio is usually used to support the diagnosis of Lewy body diseases (LBDs) and idiopathic REM sleep behavior disorder (iRBD); however, which values should be used have not been specified. Here, we hypothesized that the combination of these values is appropriate for the diagnostic purpose.In this single-center retrospective cohort study, we recruited 106 patients with LBDs or iRBD and 33 patients without those diseases, of whom we reviewed the 123I-MIBG myocardial scintigraphy results.Sensitivity/specificity to diagnose LBDs and iRBD were 0.77/0.94 for the early H/M ratio (≤ 2.0), 0.82/0.94 for the delayed H/M ratio (≤ 2.0), and 0.89/0.91 for WR (≥ 23.0). When patients were ...
TY - JOUR. T1 - Comparison of 123I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimers disease. AU - Inui, Yoshitaka. AU - Toyama, Hiroshi. AU - Manabe, Yuta. AU - Sarai, Masayoshi. AU - Iwata, Nakao. PY - 2014/10/16. Y1 - 2014/10/16. N2 - Objective: This study aimed to compare the diagnostic value of 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, N-isopropyl-p[123I]iodoamphetamine (IMP) brain perfusion single-photon emission computed tomography (SPECT), and brain magnetic resonance imaging (MRI) voxel-based morphometry (VBM) for the differentiation of dementia with Lewy bodies (DLB) and Alzheimers disease (AD).Methods: Thirty-five and 34 patients with probable DLB and probable AD, respectively, were enrolled. All patients underwent 123I-MIBG myocardial scintigraphy, 123I-IMP brain perfusion SPECT, and brain MRI. For 123I-MIBG imaging, we calculated early and delayed ...
TY - JOUR. T1 - Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy. AU - Moreira, Rita Ilhão. AU - Abreu, Ana. AU - Portugal, Guilherme. AU - Oliveira, Luís. AU - Oliveira, Mário. AU - Rodrigues, Inês. AU - Cruz, Madalena Coutinho. AU - Cunha, Pedro Silva. AU - Santos, Vanessa. AU - Clara, Helena Santa. AU - Carmo, Miguel Mota. AU - Ferreira, Rui Cruz. PY - 2020/2. Y1 - 2020/2. N2 - Background: Cardiac autonomic dysfunction as assessed by 123 I-metaiodobenzylguanidine ( 123 I-mIBG) scintigraphy is associated with poor prognosis in heart failure (HF) patients. Although cardiac resynchronization therapy (CRT) has emerged as an effective therapy in improving outcomes on HF patients, its effect on cardiac sympathetic nervous function is still not fully understood. We aimed to study the value of pre-implantation 123 I-mIBG late heart-to-mediastinum ratio (HMR) as a predictor of response and outcomes after CRT ...
Background: Iodine-123-metaiodobenzylguanidine (123I-MIBG) has been used to assess function of the cardiac sympathetic nervous system in patients with chronic heart failure. Recently, we and others demonstrated that cardiac 123I-MIBG imaging represented a prognostic marker in not only systolic heart failure (SHF) patients and but also diastolic heart failure (DHF) patients. From sub-analysis of ADMIRE-HF trial, the group of SHF patients with diabetes mellitus (DM) who presented low heart to mediastinum (H/M) ratio showed poor prognosis in other groups. Epidemiologic and experimental study demonstrated that hyperglycemia facilitated myocardial diastolic dysfunction. Therefore, we examined the influence of DM on prognostic utility of cardiac 123I-MIBG imaging in DHF patients.. Methods and Results: We performed 123I-MIBG scintigraphy and echocardiography in consecutive 128 heart failure patients with left ventricular ejection fraction ≥ 50% (71 men, mean age 64±15 years) who admitted to our ...
In the present study, we found complete defects on MIBG myocardial scans in 8 of 12 patients and limited uptake in the remaining 4 in association with severe systemic autonomic dysfunction. The incidence and magnitude of myocardial accumulation of MIBG were independent of clinical findings, including neurologic disabilities, duration of the illness, extent of endomyocardial amyloid deposition, ECG QRS voltage and ventricular wall thickness. These findings strongly suggest that cardiac adrenergic denervation due to autonomic nervous degeneration ([28]) accounts for alterations in I-123 MIBG myocardial imaging in patients with familial amyloid polyneuropathy. The presence of small localized concentrations of MIBG in the LV anterior wall in some patients indicates that myocardial sympathetic innervation is not equally impaired in this disease.. As we have previously reported ([34]), Tc-99m PYP scintigraphy may have the potential to detect early myocardial amyloid infiltration in patients with ...
In heart failure secondary to chronic mechanical overload, cardiac sympathetic neurons demonstrate depressed catecholamine synthetic and transport function. To assess the potential of sympathetic neuronal imaging for detection of depressed transport function, serial scintigrams were acquired after the intravenous administration of metaiodobenzylguanidine [131I] to 13 normal dogs, 3 autotransplanted (denervated) dogs, 5 dogs with left ventricular failure, and 5 dogs with compensated left ventricular hypertrophy due to a surgical arteriovenous shunt. Nine dogs were killed at 14 hours postinjection for determination of metaiodobenzylguanidine [131I] and endogenous norepinephrine content in left atrium, left ventricle, liver, and spleen. By 4 hours postinjection, autotransplanted dogs had a 39% reduction in mean left ventricular tracer accumulation, reflecting an absent intraneuronal tracer pool. Failure dogs demonstrated an accelerated early mean left ventricular tracer efflux rate (26.0%/hour ...
Metaiodobenzylguanidine (MIBG) is a substance that is taken up by neuroblastoma or pheochromocytoma/paraganglioma tumor cells. MIBG is combined with radioactive iodine (131 I) in the laboratory to form a radioactive compound 131 I-MIBG. This radioactive compound delivers radiation specifically to the cancer cells and causes them to die.. The purpose of this research protocol is to provides a mechanism to deliver MIBG therapy when clinically indicated, but also to provide a mechanism to continue to collect efficacy and toxicity data that will be provided. ...
In connection with clinical 131I-MIBG studies of patients with suspected pheochromocytoma and adrenomedullary hyperplasia quantitative biokinetic data have been collected in order to improve the present estimations of absorbed dose to various organs and tissues. Whole-body profiles as a function of time were measured with a whole-body counter. The retention in the total body and in the thyroid gland could be derived from the measured whole-body profiles by summing up the corresponding values. The retention of 131I-MIBG could not be exactly measured for further organs from the whole-body profiles in man. For this reason animal studies were performed with mice. The biokinetic animal data were transferred to man in form of the cumulative activity for the various organs. The mean absorbed dose for selected organs per injected activity unit was calculated using the concept of absorbed fractions (MIRD method) taking into account the radioactivity within the remaining body. Except for both the adrenal medulla
Purpose: 131I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical with activity in patients with relapsed or refractory neuroblastoma. Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan.. Experimental Design: Patients 1 to 30 years old with relapsed or refractory neuroblastoma and MIBG-avid tumors were eligible. All patients had autologous hematopoietic stem cells (PBSC) available and met standard phase I organ function requirements. Irinotecan (20 mg/m2/dose IV) was given on days 0 to 4 and 7 to 11, with vincristine (1.5 mg/m2 IV) on days 0 and 7. MIBG was given on day 1 following a 3 + 3 phase I dose escalation design starting at 8 mCi/kg MIBG. PBSCs were administered at dose level 8 mCi/kg for prolonged myelosuppression and for all patients at 12 mCi/kg or more.. Results: Twenty-four patients evaluable for dose escalation (median ...
The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCT including high-dose 131I-metaiodobenzylguanidine (MIBG) treatment. In
M. Esler; Assessment of Sympathetic Nervous Function in Humans from Noradrenaline Plasma Kinetics. Clin Sci (Lond) 1 March 1982; 62 (3): 247-254. doi: https://doi.org/10.1042/cs0620247. Download citation file:. ...
131I-Metaiodobenzylguanidine (MIBG) is a guanethi-dine derivative that is structurally similar to norepi-nephrine, and therefore concentrates in the
Our findings demonstrate striking similarities in the magnitude of sympathetically mediated coronary vasodilation between the subjects with type 1 and type 2 diabetes. The results of multivariable analysis assigned an important role to the degree of cardiac sympathetic dysfunction and the duration of diabetes in predicting the MBF response to the CPT, consistent with previous results from our laboratory (6). Importantly, plasma glucose was a statistically significant predictor of the flow response to the CPT that provided incremental information above and beyond that provided by the HED retention data and the duration of diabetes. Furthermore, the presence of type 1 (insulin deficiency) or type 2 (insulin resistance) diabetes had no significant effect on the MBF response to cold, even among those without cardiac sympathetic dysfunction. Together, these findings agree and extend previous studies in healthy volunteers (10)and in subjects with impaired glucose tolerance (11). Williams et al. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Whole-body 123I-Metaiodobenzylguanidine (mIBG) scintigraphy is used as primary image modality to visualize neuroblastoma tumours and metastases because it is the most sensitive and specific radioactive tracer in staging the disease and evaluating the response to treatment. However, especially in paediatric neuroblastoma, information from mIBG scans is difficult to extract because of acquisition difficulties that produce low definition images, with poor contours, resolution and contrast. These problems limit physician assessment. Current oncological guidelines are based on qualitative observer-dependant analysis. This makes comparing results taken at different moments of therapy, or in different institutions, difficult. In this paper, we present a computerized method that processes an image and calculates a quantitative measurement considered as its entropy, suitable for the identification of abnormal uptake regions, for which there is enough suspicion that they may be a tumour or metastatic site. This
Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. Perrone-Filardi, Pasquale; Paolillo, Stefania; Dellegrottaglie, Santo; Gargiulo, Paola; Savarese, Gianluigi; Marciano, Caterina; Casaretti, Laura; Cecere, Milena; Musella, Francesca; Pirozzi, Elisabetta; Parente, Antonio; Cuocolo, Alberto // Heart;Nov2011, Vol. 97 Issue 22, p1828 Cardiac sympathetic activity can be assessed by 123I-labelled meta-iodobenzylguanidine (MIBG) scintigraphy. Abnormalities of sympathetic cardiac activity have been shown in patients with heart failure, resulting in reduced MIBG uptake. Abnormal MIBG uptake predicts cardiac death, arrhythmias and... ...
Myocardial cells obtain 60-90% of their energy from free fatty acids under aerobic conditions. 123I-BMIPP can demonstrate fatty acid metabolism in the myocardium and is used to evaluate cardiac diseases. Forty-three patients underwent BMIPP imaging in the early (15min) and delayed (4hr) phase, and the washout rate was calculated. We evaluate the washout rate by two methods, the polar map method and the planar image method. The two methods showed close correlation (r=0.473 ...
According to recent studies, lung uptake of iodine-123-metaiodobenzylguanidine (123I-MIBG) is impaired in many lung diseases and low lung uptake of 123I-MIBG suggests endothelial dysfunction of the pulmonary artery. 123I-MIBG scintigraphy in patients with pulmonary hypertension (PH) has not yet been clinically evaluated. We hypothesized that the lung uptake of 123I-MIBG is reduced in patients with PH and differs among PH subtypes. The purpose of the present study was to analyze the lung uptake of 123I-MIBG in patients with PH and compare it with the data obtained by echocardiography or right heart catheterization ...
Duke Childrens offers the latest treatments for children with neuroblastoma including a new targeted treatment called I-131 MIBG therapy.
Some patients are at risk for life-threatening fast heart rates. These can frequently be treated by using a catheter inside the heart to burn away the cells
TY - JOUR. T1 - Influence of age and gender on iodine-123 MIBG kinetics in normal lung. AU - Kanzaki, Noriko. AU - Soda, Ryo. AU - Takahashi, Kiyoshi. AU - Sato, Keiko. AU - Hayabara, Toshiyuki. AU - Kibata, Masayoshi. AU - Takeda, Yoshihiro. AU - Hiraki, Yoshio. PY - 1998/1/1. Y1 - 1998/1/1. N2 - Iodine-123 MIBG is a biochemical marker that can be used to monitor pulmonary norepinephrine (NE) metabolism. The purpose of this study was to characterize pulmonary I-123 MIBG kinetics in relation to age and gender. Materials and Methods: Seventeen healthy volunteers and 14 patients with no cardiac or pulmonary disorders were included in this study (age range: 24 to 88 years, mean age 50.2 ± 17.6 years; 16 males, 15 females). Planar images were obtained 15 min (early) and 3 h (delayed) after injection of I-123 MIBG (111 MBq). Pulmonary uptake of I-123 MIBG was quantified based on the lung- to-mediastinum ratio (LMR) on early and delayed images. The lung clearance rate (LCR) was calculated from both ...
I-131 MIBG. Information for Physicians. AnazaoHealth, Nuclear Medicine Division, understands that your patients treatment needs are very specific. We will compound to your precise prescription, allowing you the flexibility of providing either I-131 MIBG or I-123 MIBG in your specified dose (mCi).. AnazaoHealth can provide I-131 MIBG five days a week. I-123 MIBG is available Tuesday through Thursday.. Please contact AnazaoHealth for information about these products.. ...
The aim of this review is to describe the role of nuclear imaging modalities using different radiotracers such as labeled nor-cholesterol, metaiodobenzylguanidine (MIBG) and deoxy-glucose (FDG) in the diagnostic evaluation of patients with adrenal tumours to perform lesion characterization in comparison with MR imaging.
Image of neuroblastoma using the radiopharmaceutical metaiodobenzylguanidine. The arrows identify areas of drug uptake to identify metasta
Click on this photo to see a day-by-day look at Simons MIBG therapy hospital stay. Thursday brought a real highlight: a visit by childrens author and storytime librarian Shutta Crum. Shutta read from her new book Fox and Fluff and from a family favorite All On A Sleepy Night. Thanks, Shutta!. After 4 nights in the General Clinical Research Center at the UM Hospital, Simon came home today! He was injected on Tuesday, November 5 with a high dose of I-131 MIBG (18 mCi/kg). Over the next 3 days, his body emited a rapidly decreasing amount of radioactivity, and he was cleared today to leave his cell-like hospital room.. The hardest part was having a foley catheter in place from Monday morning until Friday morning. As one of his caregivers put it, Big catheter, small penis. Simon suffered a lot of discomfort from the catheter, which was alleviated somewhat by a numbing gel (litocane) and drowsiness-inducing medications like benadryl. Since the body eliminates the radiocative substance ...
Well this is awkward... I think its been 12.. days, I dont even know quite honestly, Im completely disconnected from the world right now. I kind of left all of you hanging, I apologize for my absence. I was just having MIBG radiotherapy, no big deal, my tumours havent been very happy with me that I…
H&Ms business concept is to offer fashion and quality at the best price in a sustainable way. H&M has since it was founded in 1947 grown into one of the worlds leading fashion companies. The content of this site is copyright-protected and is the property of H&M Hennes & Mauritz AB. ...
The best Organ lessons in Camp H M Smith, HI as rated by students. Browse Camp H M Smith Organ teachers - ask questions, read reviews & compare rates!
abstractNote = {In Churg-Strauss syndrome (CSS) it is important to detect cardiac involvement, which predicts poor prognosis. This study evaluated whether {sup 123}I-metaiodobenzylguanidine (MIBG) scintigraphy could detect cardiac damage and predict cardiac events in CSS. {sup 123}I-MIBG scintigraphy was performed in 28 patients with CSS, 12 of whom had cardiac involvement. The early and delayed heart to mediastinum ratio (early H/M and delayed H/M) and washout rate were calculated by using {sup 123}I-MIBG scintigraphy and compared with those in control subjects. Early H/M and delayed H/M were significantly lower and the washout rate was significantly higher in patients with cardiac involvement than in those without and in controls (early H/M, p = 0.0024, p = 0.0001; delayed H/M, p = 0.0002, p = 0.0001; washout rate, p = 0.0012, p = 0.0052 vs those without and vs controls, respectively). Accuracy for detecting cardiac involvement was 86% for delayed H/M and washout rate and 79% for early H/M and ...
Background: Left cardiac sympathetic denervation (LCSD) suppresses ventricular arrhythmias (VAs), and reduces the incidence of sudden cardiac death (SCD). The role of bilateral cardiac sympathetic denervation (BCSD) remains unknown. The purpose of this study was to report the effects of BCSD in a small patient cohort.. Methods: We reviewed records of 6 patients (5 males, age 47-75 years, 66.7% non-ischemic cardiomyopathy) who underwent BCSD to treat severe VAs refractory to all other treatment modalities. Reversible causes of VAs were addressed in all patients. All patients were on beta-blocker therapy, and at least one antiarrhythmic drug. Five patients underwent catheter mapping with endocardial and/or epicardial ablation to control VAs (mean 2.2±0.5 ablations/patient). VAs persisted in 3 patients despite prior LCSD. Surgical BCSD was successfully performed in all patients (50% simultaneously, 50% right cardiac sympathetic denervation after prior unsuccessful LCSD).. Results: After BCSD, mean ...
TY - JOUR. T1 - Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma. T2 - A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. AU - Di Giannatale, Angela. AU - Dias-Gastellier, Nathalie. AU - Devos, Annick. AU - Mc Hugh, Kieran. AU - Boubaker, Ariane. AU - Courbon, Frederic. AU - Verschuur, Arnaud. AU - Ducassoul, Stéphane. AU - Malekzadeh, Katty. AU - Casanova, Michela. AU - Amoroso, Loredana. AU - Chastagner, Pascal. AU - Zwaan, Christian M.. AU - Munzer, Caroline. AU - Aerts, Isabelle. AU - Landman-Parker, Judith. AU - Riccardi, Riccardo. AU - Le Deley, Marie Cecile. AU - Geoerger, Birgit. AU - Rubie, Hervé. PY - 2014/1. Y1 - 2014/1. N2 - Purpose To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma. Patients and Methods This multicenter, non-randomised, phase II study included children ...
Relapsed/refractory neuroblastoma can present additional challenges on your childs treatment journey. Learn what combination of therapies your childs treatment may include.
The Specific Aim #1 of this study is to assess, with 123iodine metaiodobenzylguanidine (123I-MIBG imaging), whether cardiac resynchronization therapy (CRT) rebalances and improves the integrity and function of sympathetic nerve terminals in the failing myocardium. The study will test the hypothesis that resynchronization of biventricular contractility attenuates excessive sympathetic drive, and improves autonomic function and cardiac performance.. The Specific Aim #2 of this study is to determine the relationship between 123I-MIBG labeling of sympathetic activity and physiological measures of cardiopulmonary and autonomic function. This aim is to test the hypothesis that impaired cardiac sympathetic activity, determined by 123I-MIBG imaging will be associated with poorer submaximal exercise gas exchange (higher ventilation - carbon dioxide (CO2) slopes, low end tidal CO2, reduced oxygen pulse and a more rapid frequency response) as well as reduced heart rate power spectral frequencies, a blunted ...
TY - JOUR. T1 - Both central command and exercise pressor reflex activate cardiac sympathetic nerve activity in decerebrate cats. AU - Tsuchimochi, Hirotsugu. AU - Hayes, Shawn G.. AU - McCord, Jennifer L.. AU - Kaufman, Marc P. PY - 2009/4. Y1 - 2009/4. N2 - Both static and dynamic exercise are known to increase cardiac pump function as well as arterial blood pressure. Feedforward control by central command and feedback control by the exercise pressor reflex are thought to be the neural mechanisms causing these effects during exercise. It remains unknown as to how each mechanism activates cardiac sympathetic nerve activity (CSNA) during exercise, especially at its onset. Thus we examined the response of CSNA to stimulation of the mesencephalic locomotor region (MLR, i.e., central command) and to static muscle contraction of the triceps surae muscles or stretch of the calcaneal tendon in decerebrate cats. We found that MLR stimulation immediately increased CSNA, which was followed by a gradual ...
Parkinsons disease (PD) with autonomic dysfunction is difficult to differentiate from Parkinsonism-predominant multiple system atrophy (MSA-p). This study aimed to analyze the validity of MIBG scintigraphy for PD with autonomic dysfunction and MSA-p
Study Type: Pilot/interventional. Study Title: 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study. Study Sponsor and Collaborators: University of California, San Francisco. Purpose: To describe organ dosimetry and acute toxicities using no carrier added and carrier added 124I-MIBG PET/CT in patients with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG. Eligible Ages: 3 years or older. Eligible Genders: Both. Accepts Healthy Volunteers: No. Primary Outcome Measures: • Measurements of organ dosimetry using high specific activity (no carrier added) 124I-MIBG PET/CT (time frame: PET/CT scans on days 0-week 7). • Measurements of organ dosimetry using low specific activity (carrier added) 124I-MIBG PET/CT (time frame: PET/CT scans on days 0-week 7). • Change from baseline of blood pressure measurements at week 7 (time frame: safety assessments on days 0- week 7). • ...
A Guanidine analog with specific affinity for Tissues of the Sympathetic Nervous System and related Tumors. The radiolabeled Forms are used as Antineoplastic Agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a Neuron-blocking agent which has a strong affinity for, and Retention in, the Adrenal Medulla and also inhibits ADP-Ribosyltransferase ...
18F-N-[3-bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (18F-LMI1195) is a new class of PET tracer designed for sympathetic nervous imaging of the heart. The favorable image quality with high and specific neural uptake has been previously demonstrated in animals and humans, but intracellular behavior is not yet fully understood. The aim of the present study is to verify whether it is taken up in storage vesicles and released in company with vesicle turnover. Both vesicle-rich (PC12) and vesicle-poor (SK-N-SH) norepinephrine-expressing cell lines were used for in vitro tracer uptake studies. After 2 h of 18F-LMI1195 preloading into both cell lines, effects of stimulants for storage vesicle turnover (high concentration KCl (100 mM) or reserpine treatment) were measured at 10, 20, and 30 min. 131I-meta-iodobenzylguanidine (131I-MIBG) served as a reference. Both high concentration KCl and reserpine enhanced 18F-LMI1195 washout from PC12 cells, while tracer retention remained stable in the SK-N-SH cells. After
Background: \(^{18}\)F-N-[3-bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (\(^{18}\)F-LMI1195) is a new class of PET tracer designed for sympathetic nervous imaging of the heart. The favorable image quality with high and specific neural uptake has been previously demonstrated in animals and humans, but intracellular behavior is not yet fully understood. The aim of the present study is to verify whether it is taken up in storage vesicles and released in company with vesicle turnover. Results: Both vesicle-rich (PC12) and vesicle-poor (SK-N-SH) norepinephrine-expressing cell lines were used for in vitro tracer uptake studies. After 2 h of \(^{18}\)F-LMI1195 preloading into both cell lines, effects of stimulants for storage vesicle turnover (high concentration KCl (100 mM) or reserpine treatment) were measured at 10, 20, and 30 min. \(^{131}\)I-meta-iodobenzylguanidine (\(^{131}\)I-MIBG) served as a reference. Both high concentration KCl and reserpine enhanced \(^{18}\)F-LMI1195 washout from PC12 ...
Background: \(^{18}\)F-N-[3-bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (\(^{18}\)F-LMI1195) is a new class of PET tracer designed for sympathetic nervous imaging of the heart. The favorable image quality with high and specific neural uptake has been previously demonstrated in animals and humans, but intracellular behavior is not yet fully understood. The aim of the present study is to verify whether it is taken up in storage vesicles and released in company with vesicle turnover. Results: Both vesicle-rich (PC12) and vesicle-poor (SK-N-SH) norepinephrine-expressing cell lines were used for in vitro tracer uptake studies. After 2 h of \(^{18}\)F-LMI1195 preloading into both cell lines, effects of stimulants for storage vesicle turnover (high concentration KCl (100 mM) or reserpine treatment) were measured at 10, 20, and 30 min. \(^{131}\)I-meta-iodobenzylguanidine (\(^{131}\)I-MIBG) served as a reference. Both high concentration KCl and reserpine enhanced \(^{18}\)F-LMI1195 washout from PC12 ...
Neuroblastoma is a highly malignant tumor of children that arises in the peripheral sympathetic nervous system, and spreads widely to bones and bone marrow. The survival of children with metastatic neuroblastoma is less than 40%, despite intensive chemotherapy, radiation and bone marrow transplant. Metaiodobenzylguanidine (MIBG) is a chemical similar in structure to noradrenaline and specifically taken up by neuroblastoma, thus providing a means to detect tumor metastases and to deliver intravenous tumor-targeted radiation by attaching a radioactive iodine molecule. 131I-MIBG has achieved responses of 40% in children with relapsed neuroblastoma, with very few side effects, but due to the special requirements of administering radioactive medicines, is used at only a few centers and is not yet approved for commercial use by the FDA. Furthermore, there is very little pre-clinical data on using MIBG in combination with the new molecularly targeted drugs to provide a platform for overcoming resistant ...
The validation procedure using both features, ROIt1 and ROIt2, provided a very good classification accuracy. RF, in addition to classification also computed a percent level of confidence for the assigned class for each subject. This allowed the partition of the feature plane in high and low level of classification confidence for the two classes. The feature plane had been divided in 4 macroregions with different degree of confidence in the classification: region A-PD (high confidence), region B- PS/ET (high confidence), region C-D for both classes (low confidence). A separation threshold between the most confidence regions resulted about 1.55 for both ROIt1 and ROIt2, thus meaning that pts with uptake values lower 1.55 were classified as PD, while higher value as PS or ET. Globally, RF permitted to achieve a classification pt performance of 98.5% using ROIt1 and ROIt2 of 97.5% using only ROIt1 and 95.5% using only ROIt2, both the selected features being effective in distinguishing the difference ...
A NEMA body phantom with 6 spheres (ranging 10-37 mm) was filled with a known activity-to-volume ratio and used to determine the contrast recovery coefficient (CRC) for each visible sphere, and the measured SUV accuracy of those spheres and background water solution. One hundred eleven 123I-metaiodobenzylguanidine ([I-123] mIBG) SPECT/CT examinations from 43 patients were reconstructed using SUV SPECT® (HERMES Medical Solutions Inc.); 42 examinations were acquired using a GE Infinia Hawkeye 4 SPECT/CT, and 69 were acquired on a Siemens Symbia Intevo SPECT/CT. Inter scanner SUV analysis of 9 regions of normal [I-123] mIBG tissue uptake was conducted. Intrapatient mean SUV variability was calculated by measuring normal liver uptake within patients scanned on both cameras. The intensity of uptake by neoplastic tissue in the images was quantified using maximum SUV and, if present, compared over time.. ...
Sudomotor dysfunction testing may indicate to physicians of a patients peripheral nerve and cardiac sympathetic dysfunction. To learn more Contact Us.
I met with Lisas doctor last Thursday before her last dose of chemo of round four. We talked about what to expect during and after her MIBG Therapy scheduled for April 26. The 26th will mostly be prepping her for the Therapy that will begin on the 27th. On the 27th shell begin her treatment which will isolate her for at least 36 hours because she will be so radioactive. During those 36 hours only the medical personnel are able to enter the room in full hazmat gear to take vitals and give meds and chemo. Yes, on top of the MIBG Therapy Lisa will be receiving her 5th round of chemo. After 36 hours the level of radiation emanating from Lisa should be low enough for Linda and I to go in for short visits. After another 36 hours levels should be low enough for her to discharged. Once home with her we can expect to experience all the normal side effects of chemo and radiation treatment. Were cautioned that while we can resume our usual lifestyle, we should not sit for prolonged periods with Lisa ...
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. 61 ...
MIBG has been tested in clinical trial in the US for several years now. However, it has only been offered in a few locations throughout the US. This is a huge problem as many believe that this is a treatment that should be potentially available to every high risk neuroblastoma patient as a part of upfront therapy. I can tell you from my perspective that I have seen MIBG therapy be the single treatment capable of bringing some kids into remission. When all else failed, MIBG was the treatment that has saved some kids lives ...
Àhámọ́ jẹ́ ẹyọ aládìmú àti oníàmúṣe fún gbogbo àwọn ohun ẹlẹ́ẹ̀mì tí a mọ̀. Òhun ni ẹyọ ẹ̀mí tó kéréjùlọ tó jẹ́ tòsọ́tọ̀ bí i ohun alàyè, wọ́n sì tún ùnpé bíi òkúta ìkọ́ ẹ̀mí.[1] Àwọn ohun ẹlẹ́ẹ̀mí ṣe é tòsọ́tọ̀ bíi oníàhámọ́kan (consisting of a single cell; èyí kàkún ọ̀pọ̀ àwọn baktéríà) tàbí oníàhámọ́púpọ̀ (èyí kàkún àwọn ọ̀gbìn àti ẹranko). Ara àwọn ọmọ ènìyàn ní bíi ẹgbẹgbẹ̀rúnkẹta 100 àhámọ́; ìtóbi àhámọ́ jẹ́ 10 µm nígbàtí ìkórajọ àhámọ́ jẹ́ 1 nanogram. ...
This is the only in-depth, single author survey of heart development. It will provide a more systematic, up-to-date synthesis of the subject than any other volume, spanning the range from classical anatomical studies to recent findings in molecular biology. It also covers topics that are often omitted from discussions of heart development, such as myocardial function, cardiac innervation, and conduction development and clinical correlates will be discussed throughout.
This is the only in-depth, single author survey of heart development. It will provide a more systematic, up-to-date synthesis of the subject than any other volume, spanning the range from classical anatomical studies to recent findings in molecular biology. It also covers topics that are often omitted from discussions of heart development, such as myocardial function, cardiac innervation, and conduction development and clinical correlates will be discussed throughout.
Index of immune sensitivity (IS) of tumor cells was determined as the difference between values of log TrD50 for immune and normal animals.. The specific immunization of animals within the first 60-70 days was highly efficient and prevented the appearance of SV40 tumors in 90-100% of the animals (Fig. 5, grey columns). However, the efficiency of immune tumor prevention rapidly decreased on the 90-100th days of the latent period and was inefficient from the first day after the end of the minimal latent period (although it was long before the peak of appearance of the primary tumors) [66-68].. Thus, the period of maximal efficiency of the preventive specific immunization against the SV40 primary tumors (the first 60-70 days of the latent period) was strikingly the same as the early [H2O2CA + PGES] phenotype-negative stage in the development of these tumors when they could not yet protect themselves. And, on the contrary, the end of this naive stage (within 60-100 days of the latent period) ...
H&Ms business concept is to offer fashion and quality at the best price in a sustainable way. H&M has since it was founded in 1947 grown into one of the worlds leading fashion companies. The content of this site is copyright-protected and is the property of H&M Hennes & Mauritz AB. ...
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (May 2008). "EANM procedure guidelines for 131I-meta-iodobenzylguanidine ( ... doi:10.1007/978-3-319-68873-2. ISBN 978-3-319-68872-5. S2CID 52922868. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, ... doi:10.1007/s00259-008-0715-3. PMID 18274745. Van Vickle SS, Thompson RC (June 2015). "123I-MIBG Imaging: Patient Preparation ...
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (May 2008). "EANM procedure guidelines for 131I-meta-iodobenzylguanidine ( ... 4 KI + 2 CO 2 + O 2 ⟶ 2 K 2 CO 3 + 2 I 2 {\displaystyle {\ce {4 KI + 2 CO2 + O2 -> 2 K2CO3 + 2 I2}}} Since the iodide ion is a ... 3 December 2015. "Assessment of the Use of Potassium Iodide (KI) As a Public Protective Action During Severe Reactor Accidents ... The dose typically begins with a loading dose, then 1⁄3 mL SSKI (5 drops or 250 mg iodine as iodide), three times per day. ...
5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole MeSH D02.640.600.290 - fanft MeSH D02.640.600.308 - furagin MeSH D02.640. ... 3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide MeSH D02.092.146.325 - p-dimethylaminoazobenzene MeSH D02.092. ... vitamin k 3 MeSH D02.455.849.291.850 - taxoids MeSH D02.455.849.291.850.777 - paclitaxel MeSH D02.455.849.365 - dolichol MeSH ... 3-diketogulonic acid MeSH D02.241.081.844.300 - glucaric acid MeSH D02.241.081.844.322 - gluconates MeSH D02.241.081.844. ...
Iodobenzylguanidine. J Nucl Med 25:2-6, 1984 Carpi, Angelo; Mechanick, Jeffrey I. (2016). Thyroid Cancer: From Emergent ... 81 (8): 2930-3. doi:10.1210/jcem.81.8.8768854. PMID 8768854. Lawrence, J. E.; Lamm, S. H.; Pino, S.; Richman, K.; Braverman, L ... The majority of I-131 will be eliminated from the human body in 3-5 days, through natural decay, and through excretion in sweat ... 1 (3): 197-203. doi:10.1023/A:1010031115233. ISSN 1389-9155. PMID 11705004. S2CID 13575769. Frot, Jacques. "The Causes of the ...
Another way to detect neuroblastoma is the meta-iodobenzylguanidine scan, which is taken up by 90 to 95% of all neuroblastomas ... ISBN 978-3-540-26616-7. Beckwith JB, Perrin EV (December 1963). "In Situ Neuroblastomas: A Contribution to the Natural History ... 45 (3): 402-411. doi:10.1007/s00259-017-3856-4. ISSN 1619-7089. Albers, Anne R; O'Dorisio, M. Sue; Balster, Douglas A; Caprara ... 115 (3-4): 273-282. doi:10.1159/000095924. PMID 17124410. S2CID 14012430. Carén H, Erichsen J, Olsson L, Enerbäck C, Sjöberg RM ...
"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy" (PDF). 17 June 2009. Archived from the ... 29 (1-3): 185-205. ISSN 0393-9375. "Where do we get iodine from?". Iodine Global Network. Archived from the original on 13 ... 851-3 Greenwood and Earnshaw, pp. 853-9 Greenwood and Earnshaw, pp. 863-4 Greenwood and Earnshaw, pp. 872-5 Greenwood and ... ISBN 978-3-540-93516-2. Greenwood and Earnshaw, pp. 804-9 Windholz, Martha; Budavari, Susan; Stroumtsos, Lorraine Y.; Fertig, ...
... meta-iodobenzylguanidine (MIBG) imaging for neuroendocrine tumors, heat-damaged red blood cell imaging for identifying ectopic ... 1996 Jul;26(3):191-193. PMID 8829280. PET center of excellence ABNM brochure Archived 2007-07-01 at the Wayback Machine nuclear ...
Iodine-123-meta-iodobenzylguanidine myocardial scintigraphy can help find denervation of the muscles around the heart, which ... 9 (Suppl 3): 23-30. doi:10.1046/j.1468-1331.9.s3.3.x. PMID 12464118. Gibb WR, Lees AJ (June 1988). "The relevance of the Lewy ... Males are more often affected than females at a ratio of around 3:2. When it is seen in people before the age of 50, it is ... Davis P (3 May 2007). "Michael J. Fox". The Time 100. Time. Archived from the original on 25 April 2011. Retrieved 2 April 2011 ...
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced ... Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [QxMD MEDLINE ... Type I, 1 cm to , 2 cm: Surveillance with repeat endoscopy every 3 years or endoscopic resection ... Observation for clinically indolent disease with imaging and biomarkers (if functional) every 3 months ...
Radionuclide therapy ( 131I-MIBG [iodine-131/meta-iodobenzylguanidine], DOTATOC) * Systemic chemotherapy (eg, temozolomide/CVD ... After complete resection, follow up with radiologic imaging every 3 months for 2 years, then every 3-6 months for at least ... Type I, 1 cm to , 2 cm: Surveillance with repeat endoscopy every 3 years or endoscopic resection ... Observation for clinically indolent disease with imaging and biomarkers (if functional) every 3 months ...
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced ... 1, 3, 4, 45, 46, 47, 48, 49] midgut (with metastasis), prostate, ovaries, kidneys, [26] and testes. [50, 51] ... Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [QxMD MEDLINE ... 65, 66] In 5 of 9 typical carcinoid tumors of the lung, 3 distinct regions of allelic loss were identified at bands 11q13.1 ( ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ...
... meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism Relat Disord. 2011 Nov. 17(9):698-700. [QxMD ... 3] categorized MSA in MSA-P with predominant parkinsonism and MSA-P with dominant cerebellar features (MSA-C). (See Categories ... OH is defined as blood pressure fall by at least 30mm Hg systolic and 15mm Hg diastolic within 3 minutes of standing from a ... 10] and genetic alterations with abnormal expansion of 1 allele of the SCA type 3 gene has been reported. [11] Single ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ... Although pheochromocytomas have classically been associated with 3 syndromes-von Hippel-Lindau (VHL) syndrome, multiple ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ... In the absence of these 3 symptoms and hypertension, the diagnosis may be excluded. ...
An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation. 1994 Feb. 89(2):667-83. [QxMD MEDLINE Link]. ... 3) specific fat-sensitive or fat-suppressive imaging to confirm fatty infiltration or transdifferentiation on short-axis views ... 3-dimensional echocardiography, cardiovascular magnetic resonance with late enhancement, and electroanatomic voltage mapping. [ ... 3) patients with palpitations, syncopal episodes, or echocardiographic abnormalities of the right ventricle; and (4) patients ...
Radionuclide therapy ( 131I-MIBG [iodine-131/meta-iodobenzylguanidine], DOTATOC) * Systemic chemotherapy (eg, temozolomide/CVD ... After complete resection, follow up with radiologic imaging every 3 months for 2 years, then every 3-6 months for at least ... Type I, 1 cm to , 2 cm: Surveillance with repeat endoscopy every 3 years or endoscopic resection ... Observation for clinically indolent disease with imaging and biomarkers (if functional) every 3 months ...
Radionuclide therapy ( 131I-MIBG [iodine-131/meta-iodobenzylguanidine], DOTATOC) * Systemic chemotherapy (eg, temozolomide/CVD ... After complete resection, follow up with radiologic imaging every 3 months for 2 years, then every 3-6 months for at least ... Type I, 1 cm to , 2 cm: Surveillance with repeat endoscopy every 3 years or endoscopic resection ... Observation for clinically indolent disease with imaging and biomarkers (if functional) every 3 months ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ... Surgical mortality rates are less than 2-3% when the operation is performed by a surgeon and an anesthesiologist who are ... the pooled recurrence rate for sporadic pheochromocytomas is 3%. The weighted mean time to recurrence in the study was 49.4 ...
A subsequent meta-iodobenzylguanidine scan (a nuclear medicine examination that depicts noradrenergic tissue) showed a chest ...
... by Ewing test and iodine-123 meta-iodobenzylguanidine [123 I-MIBG] myocardial scanning) have been reported to have limited ... This scan was taken 6 months after the scan shown in Pictures 3, 4, and 5. Both the right and left optic nerves are enlarged ... All 3 modalities of EPs can show abnormalities in patients before the appearance of clinical signs. ...
... meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism Relat Disord. 2011 Nov. 17(9):698-700. [QxMD ... OH is defined as blood pressure fall by at least 30mm Hg systolic and 15mm Hg diastolic within 3 minutes of standing from a ... Nirenberg MJ, Libien J, Vonsattel JP, Fahn S. Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene ... A positive response to levodopa is defined as a significant improvement of motor features during 3 months' application of ...
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced ... 1, 2, 3, 4] They can be seen in other organs, [5] including the lungs, [6] mediastinum, thymus, [7] liver, bile ducts, [8] ... Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [QxMD MEDLINE ... 3) tubules and glands or rosettelike patterns; (4) poorly differentiated or atypical patterns; and (5) mixed patterns. A ...
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced ... 1, 2, 3, 4] They can be seen in other organs, [5] including the lungs, [6] mediastinum, thymus, [7] liver, bile ducts, [8] ... Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [QxMD MEDLINE ... 3) tubules and glands or rosettelike patterns; (4) poorly differentiated or atypical patterns; and (5) mixed patterns. A ...
Radionuclide therapy ( 131I-MIBG [iodine-131/meta-iodobenzylguanidine], DOTATOC) * Systemic chemotherapy (eg, temozolomide/CVD ... After complete resection, follow up with radiologic imaging every 3 months for 2 years, then every 3-6 months for at least ... Type I, 1 cm to , 2 cm: Surveillance with repeat endoscopy every 3 years or endoscopic resection ... Observation for clinically indolent disease with imaging and biomarkers (if functional) every 3 months ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ... Although pheochromocytomas have classically been associated with 3 syndromes-von Hippel-Lindau (VHL) syndrome, multiple ...
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced ... 1, 2, 3, 4] They can be seen in other organs, [5] including the lungs, [6] mediastinum, thymus, [7] liver, bile ducts, [8] ... Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [QxMD MEDLINE ... 3) tubules and glands or rosettelike patterns; (4) poorly differentiated or atypical patterns; and (5) mixed patterns. A ...
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced ... 1, 3, 4, 45, 46, 47, 48, 49] midgut (with metastasis), prostate, ovaries, kidneys, [26] and testes. [50, 51] ... Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [QxMD MEDLINE ... 65, 66] In 5 of 9 typical carcinoid tumors of the lung, 3 distinct regions of allelic loss were identified at bands 11q13.1 ( ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ... Surgical mortality rates are less than 2-3% when the operation is performed by a surgeon and an anesthesiologist who are ... the pooled recurrence rate for sporadic pheochromocytomas is 3%. The weighted mean time to recurrence in the study was 49.4 ...
Single photon emission computed tomography of heart using iodine 123 meta-iodobenzylguanidine Current Synonym true false ... Single photon emission using iodine 123 meta-iodobenzylguanidine computed tomography with computed tomography of heart ( ... Single photon emission computed tomography of heart using iodine 123 meta-iodobenzylguanidine (procedure) {440043007 , SNOMED- ... Single photon emission computed tomography of heart using iodine 123 meta-iodobenzylguanidine (procedure). ...
Assessment of cardiac adrenergic supply in mitral valve prolapse using m-[123I]iodobenzylguanidine scintigraphy. Int J Cardiol ... Atrioventricular valve morphology and dynamics in congenital heart disease as imaged with real-time 3-dimensional matrix-array ... Accuracy of real-time 3-dimensional echocardiography in the assessment of mitral prolapse. Is transesophageal echocardiography ...
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (May 2008). "EANM procedure guidelines for 131I-meta-iodobenzylguanidine ( ... doi:10.1007/978-3-319-68873-2. ISBN 978-3-319-68872-5. S2CID 52922868. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, ... doi:10.1007/s00259-008-0715-3. PMID 18274745. Van Vickle SS, Thompson RC (June 2015). "123I-MIBG Imaging: Patient Preparation ...
A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. ... Adrenal medullary imaging; Meta-iodobenzylguanidine scintiscan; Pheochromocytoma - MIBG; Neuroblastoma - MIBG; Carcinoid MIBG ... You may need to return for repeated scans for 1 to 3 days. Each scan takes 1 to 2 hours. ...
Petretta M, Pellegrino T, Cuocolo A. Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure: Implications ... Petretta, M, Pellegrino, T & Cuocolo, A 2014, Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure: ... T1 - Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure. T2 - Implications of endpoint selection and ... Petretta, M., Pellegrino, T., & Cuocolo, A. (2014). Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart ...
We wish to acknowledge and thank the US National Library of Medicine and Medline staff for providing access to their data ...
Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980;21:349 ... Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet. 1984;1:333-334. ... 3). Thus, 123I-MIBG and 18F-FDG scans may both be needed at major decision points during therapy to exclude residual disease ... FIGURE 3. A 3-year-old boy with stage 4 neuroblastoma before bone marrow transplantation. (A) 18F-FDG anterior maximum- ...
Another imaging technique uses meta-iodobenzylguanidine, or MIBG, to assess neuronal dysfunction in various cardiovascular ... Imaging 2010;3(8):893-895.. Moreno PR. The high-risk thin-cap fibroatheroma: a new kid on the block. Circ. Cardiovasc. Interv. ... Med. 2011;3(104):104ra101.. Isern J, Méndez-Ferrer S. Stem cell interactions in a bone marrow niche. Curr. Osteoporos. Rep. ... Phase 3 trials are now underway.. One potential drawback of this approach is that about half of heart failure patients have pre ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ...
... spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42. Porzig A ...
Adenovirus (type C subtype 3) infection coincided with manifestation. Data on treatment, imaging and follow-up are provided. In ... No neuroblastoma was found by abdominal ultrasound, chest X-ray and meta-iodo-benzylguanidine scintigraphy. Due to positive ... Due to persisting tremor and irritability, therapy was switched to oral dexamethasone (12 mg each on 3 days monthly) after 1 ... Adenovirus (type C subtype 3) infection coincided with manifestation. Data on treatment, imaging and follow-up are provided. In ...
TY - JOUR. T1 - Iodine-131 metaiodobenzylguanidine treatment for metastic carcinoid. T2 - Results in 98 patients. AU - Safford, Shawn D.. AU - Coleman, R. Edward. AU - Gockerman, Jon P.. AU - Moore, Joseph. AU - Feldman, Jerome. AU - Onaitis, Mark W.. AU - Tyler, Douglas S.. AU - Olson, John A.. PY - 2004/11/1. Y1 - 2004/11/1. N2 - BACKGROUND. Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic utility of high-dose 131I-MIBG treatment in a large group of patients with metastatic carcinoid tumors. METHODS. The authors performed a retrospective review of 98 patients with metastatic carcinoid who were treated at their institution with 131I-MIBG over a 15-year period. Endpoints examined included the World Health Organization criteria for treatment response: symptoms, hormone (5-hydroxyindoleacetic acid [5-HIAA]) ...
Maruoka, Y., Abe, K., Baba, S., Isoda, T., Sawamoto, H., Tanabe, Y., Sasaki, M. & Honda, H., 2012, In: Radiology. 265, 3, p. ... 3, p. 167-172 6 p.. Research output: Contribution to journal › Article › peer-review ...
Intracellular acidification of human melanoma xenografts by the respiratory inhibitor m-iodobenzylguanidine plus hyperglycemia ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ... Although pheochromocytomas have classically been associated with 3 syndromes-von Hippel-Lindau (VHL) syndrome, multiple ...
Purpose More than two decades ago, an international working group established the International Neuroblastoma Response Criteria (INRC) to assess treatment response in children with neuroblastoma. However, this system requires modification to incorporate modern imaging techniques and new methods for quantifying bone marrow disease that were not previously widely available. The National Cancer Institute sponsored a clinical trials planning meeting in 2012 to update and refine response criteria for patients with neuroblastoma. Methods Multidisciplinary investigators from 13 countries reviewed data from published trials performed through cooperative groups, consortia, and single institutions. Data from both prospective and retrospective trials were used to refine the INRC. Monthly international conference calls were held from 2011 to 2015, and consensus was reached through review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeting leadership council. ...
Esser, P. D., Halpern, E. J. & Amis, E. S., Nov 1991, In: Journal of Digital Imaging. 4, 4, p. 248-250 3 p.. Research output: ... Kim, A. E., Haramati, L. B., Janus, D. & Borczuk, A., Apr 1999, In: Journal of Thoracic Imaging. 14, 2, p. 135-137 3 p.. ... Erlichman, D. B., Stein, M. W., Weiss, A. & Mazzariol, F., Jun 1 2016, In: Emergency Radiology. 23, 3, p. 245-249 5 p.. ... Weiss, M. A., Koenigsberg, M. & Freeman, L. M., Dec 1 1975, In: Journal of Nuclear Medicine. 16, 3, p. 180-182 3 p.. Research ...
2019, In: Clin Cancer Res. 25, 3, blz. 1012-1021 10 blz.. Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review ... 2020, In: Cancers. 12, 3. Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review ... 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in ... 3. Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review ...
Y1 - 1999/3/2. N2 - A 74-year-old woman underwent I-131 MIBG imaging to rule out or confirm a left adrenal pheochromocytoma. ... 3, 02.03.1999, p. 192-193.. Research output: Contribution to journal › Article › peer-review ...
This graph shows the total number of publications written about "Technetium Tc 99m Medronate" by people in Harvard Catalyst Profiles by year, and whether "Technetium Tc 99m Medronate" was a major or minor topic of these publication ...
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced ... Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [QxMD MEDLINE ... Type I, 1 cm to , 2 cm: Surveillance with repeat endoscopy every 3 years or endoscopic resection ... Observation for clinically indolent disease with imaging and biomarkers (if functional) every 3 months ...
... iodine-131/123 meta-iodo-benzylguanidine (131/123I-MIBG) to be actively transported and stored within neurosecretory granules ... Tyr3]octreotide (68Ga-DOTATOC), [68Ga-DOTA0,Tyr3]octreotate (68Ga- DOTATATE) and 68Ga-DOTANOC for sstr binding, 18F-DOPA, 11C-5 ...
... whereas its inhibition by meta-iodobenzylguanidine decreases migration of liver cancer cells [33]. Cigarette smoke extract (CSE ... Ya-Ling Hsu1, Jen-Yu Hung2,3, Yung-Yu Liang1, Yi-Shiuan Lin1, Ming-Ju Tsai1,2, Shah-Hwa Chou4, Chi-Yu Lu5 and Po-Lin Kuo6,7 ... Figure 3: Overexpression of S100P protein caused EMT and increased cell migration and invasion. A. The expression of S100P in ... The PCR reaction was conducted with a denaturation step at 95°C for 20 sec, 40 cycles at 95°C for 3 sec, and 60°C for 30 sec. ...
131I-meta-iodobenzylguanidine scintigraphy in patients with a suspected pheochromocytoma. A comparison with CT and biohumoral ... A comparison between scintigraphy with 131I-meta-iodobenzylguanidine, computed tomography and echography (234 views). Radiol ... Cardiac Neuronal Imaging With 123i-Meta-Iodobenzylguanidine In Heart Failure: Implications Of Endpoint Selection And ... Haema (ISSN: 1108-2682), 2004; 7(3): 329-334.. Impact Factor: 0. View Export to BibTeX Export to EndNote. Fonti R, Del Vecchio ...
... followed with I-123-beta-metyl-iodophenyl pentadecanoic acid and I-123-meta-iodobenzyl-guanidine myocardial scintigraphy. ... Kikuchi, E., Tanomogi, H. & Hasegawa, S., 1998 Nov 1, In: Acta Urologica Japonica. 44, 11, p. 825-827 3 p.. Research output: ... Masuoka, A., Kimura, N., Katogi, T. & Suzuki, T., 2014 Sep, In: Asian Cardiovascular and Thoracic Annals. 22, 7, p. 846-848 3 p ... Nishihara, K., Tohyama, M. & Kubo, A., 2019 May 1, In: Pediatric Dermatology. 36, 3, p. 368-371 4 p.. Research output: ...
... radioactive labelled octreotide and meta-iodobenzylguanidine (MIBG) (2,42). Radiofrequency ablation which is being increasingly ... 5%-50 9%) and cross-sectional imaging (34 0%-16 3%) between the. Posted on July 7, 2016. by pdgf0624 ... Suspicious findings on either CT and/or bone scan prompted additional imaging studies GSK-3 in 27 patients, none of which ... for 4 weeks, then once every 2 weeks for 8 weeks, then once monthly for 3 months) Inhibitors,research,lifescience,medical for ...
Nitrosylated derivatives of guanidine. They are used as MUTAGENS in MOLECULAR BIOLOGY research ...
Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a ... Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG ... 2017 06; 17(3):e155-e159. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. PMID ... 2018 11 02; 3(21). Behr SC, Villanueva-Meyer JE, Li Y, Wang YH, Wei J, Moroz A, Lee JK, Hsiao JC, Gao KT, Ma W, Cha S, Wilson ...
Ando Y, Obayashi K, Tanaka Y, Tsuji T, Uchino M, Takahashi M, Ando M. Radiolabelled meta-iodobenzylguanidine in assessment of ... Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive ... 3. Gadolinium-enhanced cardiac magnetic resonance imaging in a patient with ATTRwt amyloidosis. a Late gadolinium enhancement ... 3) [68, 69]. LGE transfers from the subendocardial pattern to the transmural pattern as the disease progresses [70]. As LGE ...
  • Petretta, M, Pellegrino, T & Cuocolo, A 2014, ' Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure: Implications of endpoint selection and quantitative analysis on clinical decisions ', European Journal of Nuclear Medicine and Molecular Imaging , vol. 41, no. 9, pp. 1663-1665. (elsevier.com)
  • 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of meta-analysis. (veterinarniportal.cz)
  • RESULTS: Total cfDNA concentrations in blood plasma from patients with high-risk neuroblastoma were higher than in healthy controls and consistently correlated with neuron-specific enolase levels and lactate dehydrogenase activity but not with 123I-meta-iodobenzylguanidine scores at relapse diagnosis. (mdc-berlin.de)
  • A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. (medlineplus.gov)
  • For stage 3 neuroblastoma (15 scans, 10 patients), 123 I-MIBG depicted more extensive primary neuroblastoma or local or regional metastases in 5 of 15 scans. (snmjournals.org)
  • Part 3 will potentially be conducted as an additional expansion phase of the idasanutlin combination cohorts in neuroblastoma, AML, or ALL for further response and safety assessment. (cardiff.ac.uk)
  • [2] [3] Of cancer deaths in children, about 15% are due to neuroblastoma. (wikizero.com)
  • Mutations in anaplastic lymphoma kinase (ALK) oncogene and PHOX2B account for the majority of hereditary neuroblastoma ( 2 , 3 ). (unboundmedicine.com)
  • Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). (ucsf.edu)
  • 131-I-meta-iodobenzylguanidine for the diagnosis and treatment of pheochromocytoma. (unito.it)
  • 123 I-MIBG and 18 F-FDG showed equal numbers of lesions in 1 of 13 scans, and 3 of 13 scan results were normal. (snmjournals.org)
  • La scintigraphie au MIBG utilise une substance radioactive appelée iode méta-iodobenzylguanidine (MIBG) comme traceur de la circulation sanguine. (padiracinnovation.org)
  • There was a trend suggesting that patients with lung-only stage 3 or 4 relapse might benefit from autologous HCT. (southcarolinablues.com)
  • Although pheochromocytomas have classically been associated with 3 syndromes-von Hippel-Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN 2), and neurofibromatosis type 1 (NF1)-there are now 10 genes that have been identified as sites of mutations leading to these tumors. (medscape.com)
  • WHO 3-29 patients, 17 foregut and 9 midgut tumors, and 3 of unknown origin. (nel.edu)
  • WHO 4-7 patients, including 4 foregut and 3 midgut neoplasms. (nel.edu)
  • 15% [ 2 , 3 ], with metastasis as the major cause of treatment failure. (oncotarget.com)
  • The degree of amplification shows a bimodal distribution: either 3- to 10-fold, or 100- to 300-fold. (wikizero.com)
  • MYCN oncogene amplification and mutations at chromosome 11q are used as markers for prognostication and treatment stratification ( 3 ). (unboundmedicine.com)
  • Clinical, laboratory, and Doppler echocardiographic variables were evaluated at baseline and after 3 and 6 months. (bvsalud.org)
  • NB reportedly shows several heterogeneous clinical behaviours ( 3 ). (iiarjournals.org)
  • FDG-PET seems to be a very attractive imaging functional modality in case of patients with WHO 3 and WHO 4. (nel.edu)
  • En outre, une analyse du transcriptome des miARN de l'exosome sérique et une analyse du métabolome plasmatique suivie d'une analyse trans-omique ont été effectuées chez des patients atteints de la maladie de Parkinson de novo et des personnes témoins en bonne santé appariées selon l'âge. (padiracinnovation.org)
  • We only provide this product sheet to customers who have purchased this biosafety level 3 product. (atcc.org)
  • Adenovirus (type C subtype 3) infection coincided with manifestation. (springeropen.com)
  • Due to positive polymerase chain reaction (PCR) for adenovirus type C subtype 3 in serum (2800 copies/ml) on day 3 after admittance, a parainfectious OMS was suspected. (springeropen.com)
  • [3] The disease was first described in the 1800s. (wikizero.com)
  • As the result, the population of neurodegenerative disease will increase as along and probably bring a huge burden to Chinese economics and healthcare system [ 3 ]. (biomedcentral.com)
  • To determine the feasibility of performing Curie scores in "real time," as assessed by central scan committee review of a 123 I-meta-iodobenzylguanidine (MIBG) scan obtained after cycle 4 of induction therapy. (ucsf.edu)
  • This scanning procedure injects a radioactive material called iodine-123-meta-iodobenzylguanidine (MIGB), the most sensitive and specific radioactive tracer used for the diagnosis and monitoring of neuroectodermal & neuroendocrine tumors. (esticastresearch.com)
  • For example: 1) Generally the capital cost is 747 122 CHAPTER 3. (qrforex.com)
  • EXPLORATORY OBJECTIVES: I. To determine the incidence of non-hematologic organ toxicity (grade 3 and higher) and all cause mortality in patients undergoing autologous stem cell transplant with a BuMel based regimen followed by local radiotherapy for the treatment of high-risk neuroblastoma. (ucsf.edu)
  • After completion of study treatment, patients are followed up every 3 months for 1 year, and then every 6 months for 4 years. (ucsf.edu)
  • The catheter will be removed 3-5 days following the treatment. (clinicaltrials.gov)
  • 15% [ 2 , 3 ], with metastasis as the major cause of treatment failure. (oncotarget.com)
  • This was an open-label, randomized, 5-treatment, 5-period, 3-way crossover study in 15 healthy subjects. (permanent-makeup-sandhausen.de)
  • Treatment repeats every 3 weeks for 2 courses. (ucsf.edu)
  • Treatment repeats every 3 weeks for 1 course. (ucsf.edu)
  • COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3 and filgrastim subcutaneously (SC) or IV once daily (QD) beginning on day 6 or pegfilgrastim SQ once on day 6. (ucsf.edu)
  • COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, doxorubicin hydrochloride IV over 24 hours on days 1-3 and mesna IV over 15-30 minutes on days 1-2 and filgrastim subcutaneously (SC) or IV once daily (QD) beginning on day 6 or pegfilgrastim SQ once on day 6. (ucsf.edu)
  • CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. (ucsf.edu)